ISSN: 2476-2253

Journal of Cancer Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Cancer Diagn 2016, Vol 1(1): 107
  • DOI: 10.4172/2476-2253.1000107

Personalised Dosing of Hyperthermia

Gyula Peter Szigeti1, Oliver Szasz2* and Gabriella Hegyi3
1Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Hungary
2Department of Biotechnics, Szent Istvan University, Hungary
3Department of Complementary Medicine, Medical School, University of Pecs, Hungary
*Corresponding Author : Oliver Szasz, Department of Biotechnics, Szent Istvan University, Hungary, Tel: +36-23-555-510, Fax: +36-23-555-515, Email: biotech@gek.szie.hu

Received Date: Sep 19, 2016 / Accepted Date: Oct 27, 2016 / Published Date: Nov 12, 2016

Abstract

Objective: Our objective is to show the superiority of the membrane selection and connected energy dose fixed via personal sensing.

Method: Hyperthermia in oncology involves heating malignant cells and causing thermal damage in an attempt to destroy them. This could be immediate (necrotic) cell-distortion and ignite natural cell elimination, like apoptosis or autophagy.

Two concepts determine the dose of hyperthermia: (1) isothermal tumour heating, homogeneous tumour temperature, which is used for necrosis based cumulative equivalent minutes (CEM), and (2) inhomogeneous heating of the tumour following the heterogeneity of the lesion itself. The personalized dosing used by oncothermia is heterogenic, it selects the membrane rafts of malignant cells that sense temperature on a cellular level targeting the nano-clusters of transmembrane proteins. The method uses the standard specific energy dosing controlled by personal sensing of the treated patient maintaining homeostatic control through gradual step-up heating process.

Results: The nano excitation is thermal (fits to Arrhenius plot), and acts directly on the membrane of malignant cells. The homeostatic physiology reactions do not suppress the effective hyperthermia action with this heating. The stress reactions could be more regulated, the vasocontraction and vasodilatation effects roughly compensate each other. This allows a clear measurability of the dose of the treatment: instead of the temperature based cumulative equivalent minutes (CEM) it uses absorbed energy controlled by the RF-circuit. Due to the small mass of targets the applied power is low, the energy-sink surface cooling is fixed to homeostasis ensuring the accuracy of the energydose and improving the safety of the hyperthermia method.

Conclusion: The nanoselection of malignant cells via oncothermia allows us to return to the dosing “gold standard,” which is also applied in radiotherapy. This energy-based dose is personalised with accurate step-up heating taking the wash-out time and the personal sensing of the patient into account.

Keywords: Hperthermia; Oncothermia; Dose; Personalisation; Heat sensing; Step-up heating; Homeostasis; Fight-or-flight reaction

Citation: Szigeti GP, Szasz O, Hegyi G (2016) Personalised Dosing of Hyperthermia. J Cancer Diagn 1:107. Doi: 10.4172/2476-2253.1000107

Copyright: © 2016 Szigeti GP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top